Anti diabetic Biosimilars Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023
Anti diabetic Biosimilars Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023
Global Anti diabetic Biosimilars Market: By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, α-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others),By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography –Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Market Outline: Anti diabetic Biosimilars Market
Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.
A sample of this report is available upon request @
Market Dynamics: Anti diabetic Biosimilars Market
Drivers:
- Increase in the prevalence of diabetic patients
- Patent expiries block buster drugs and promising product pipeline
- Government initiations to control the diabetes
Restraints:
- High cost of R&D activities
- Stringent regulatory policies
- Complexity in development of biosimilars
To view TOC of this report is available upon request @
Market Scope: Anti diabetic Biosimilars Market
Global anti-diabetic biosimilars market is segmented on the basis of drug class, disease type, distribution channel, and region
Based on the drug class, anti-diabetic biosimilars market is segmented into the following:
- Insulin
- Biguanides
- Sulfonyl Ureas
- Thiazolidinediones
- Di Peptidyl Peptidase (DPP)-IV Inhibitors
- α-glucosidase Inhibitos
- GLP-1 Agonists
- Others
Based on the disease type, anti-diabetic biosimilars market is segmented into the following:
- Type-I Diabetes
- Type-II Diabetes
Based on the distribution channel, anti-diabetic biosimilars market is segmented into the following:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Based on the region, anti-diabetic biosimilars market is segmented into the following:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Need more information about this report @
Competition Assessment: Anti diabetic Biosimilars Market
Some of the players in the global anti-diabetic biosimilars market include:
- Biocon (India)
- Merck Sharp & Dohme Corporation (U.S.)
- Boehringer Ingelheim GmbH (Germany)
- Eli Lilly & Co. (U.S.)
- Sanofi-aventis U.S. LLC (U.S.)
- Samsung Bioepis (Samsung BioLogics) (South Korea)
- Mylan N.V. (U.S.)
- Wockhardt (India)
Notable Market Developments: Anti-diabetic Biosimilars Market
- In May 2017, Sanofi received Committee for Medicinal Products for Human Use (CHMP) recommendation for approval of Insulin Lispro Biosimilar
Key Features of the Report:
- The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key marketdevelopments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/anti-diabetic-biosimilars-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised which follow a holistic approach to solve needs of market research services based on our client needs.
Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.
Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
